MX2021002998A - Compuestos de triazolo-pirimidina y usos de los mismos. - Google Patents

Compuestos de triazolo-pirimidina y usos de los mismos.

Info

Publication number
MX2021002998A
MX2021002998A MX2021002998A MX2021002998A MX2021002998A MX 2021002998 A MX2021002998 A MX 2021002998A MX 2021002998 A MX2021002998 A MX 2021002998A MX 2021002998 A MX2021002998 A MX 2021002998A MX 2021002998 A MX2021002998 A MX 2021002998A
Authority
MX
Mexico
Prior art keywords
compounds
triazolo
pyrimidine compounds
present disclosure
cancer
Prior art date
Application number
MX2021002998A
Other languages
English (en)
Inventor
Zhenfan Yang
changhe Qi
Xiaolin Zhang
Honchung Tsui
Qingbei Zeng
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2021002998A publication Critical patent/MX2021002998A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Nuevos compuestos de triazolo-pirimidina dirigidos hacia los receptores de adenosina (especialmente A1 y A2, particularmente A2a). También, composiciones farmacéuticas que comprenden uno o más de los compuestos como ingredientes activos, y el uso de los compuestos en el tratamiento de enfermedades asociadas con el receptor de adenosina (AR), por ejemplo, cáncer, tal como NSCLC, RCC, cáncer de próstata y cáncer de mama.
MX2021002998A 2018-09-12 2019-09-12 Compuestos de triazolo-pirimidina y usos de los mismos. MX2021002998A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018105220 2018-09-12
PCT/CN2019/105591 WO2020052631A1 (en) 2018-09-12 2019-09-12 Triazolo-pyrimidine compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2021002998A true MX2021002998A (es) 2021-05-14

Family

ID=69778192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002998A MX2021002998A (es) 2018-09-12 2019-09-12 Compuestos de triazolo-pirimidina y usos de los mismos.

Country Status (12)

Country Link
US (2) US10858365B2 (es)
EP (1) EP3849983A4 (es)
JP (1) JP2022500402A (es)
KR (1) KR20210075996A (es)
CN (3) CN111601809A (es)
AR (1) AR116315A1 (es)
AU (1) AU2019340767A1 (es)
BR (1) BR112021004774A2 (es)
CA (1) CA3111869A1 (es)
MX (1) MX2021002998A (es)
TW (1) TWI820209B (es)
WO (1) WO2020052631A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110662544A (zh) * 2017-03-24 2020-01-07 纳诺森公司 具有有用的药学应用的稠合***并嘧啶化合物
EP3654978A4 (en) 2017-07-18 2021-03-31 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSIN ANTAGONISTS
TW202400599A (zh) * 2018-02-27 2024-01-01 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及***并嘧啶
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
TW202402759A (zh) 2018-07-05 2024-01-16 美商英塞特公司 作為a2a/a2b抑制劑之稠合吡嗪衍生物
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
KR20220066074A (ko) * 2019-08-26 2022-05-23 인사이트 코포레이션 A2a / a2b 억제제로서의 트리아졸로피리미딘
WO2021156439A1 (en) 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743910B2 (en) * 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
JPWO2002079204A1 (ja) * 2001-03-28 2004-07-22 協和醗酵工業株式会社 ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
AR038366A1 (es) * 2001-11-30 2005-01-12 Schering Corp Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
CA2500228A1 (en) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]-triazolo[1,5-c]pyrimidine derivative
AU2018210272B2 (en) * 2017-01-20 2022-02-24 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 ***并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202400599A (zh) * 2018-02-27 2024-01-01 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及***并嘧啶
JP7406691B2 (ja) * 2018-04-28 2023-12-28 イノレイク・バイオファーマ（ハンジョウ）・カンパニー・リミテッド トリアゾロピリミジン系化合物の結晶形、塩のタイプおよびその調製方法
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos

Also Published As

Publication number Publication date
AU2019340767A1 (en) 2021-04-08
US10858365B2 (en) 2020-12-08
TW202024089A (zh) 2020-07-01
AR116315A1 (es) 2021-04-21
US11629147B2 (en) 2023-04-18
BR112021004774A2 (pt) 2021-08-03
EP3849983A1 (en) 2021-07-21
CA3111869A1 (en) 2020-03-19
JP2022500402A (ja) 2022-01-04
TWI820209B (zh) 2023-11-01
CN112279852A (zh) 2021-01-29
CN111635408A (zh) 2020-09-08
US20210009600A1 (en) 2021-01-14
WO2020052631A1 (en) 2020-03-19
CN111601809A (zh) 2020-08-28
CN111635408B (zh) 2022-07-22
US20200331918A1 (en) 2020-10-22
KR20210075996A (ko) 2021-06-23
CN112279852B (zh) 2023-01-17
EP3849983A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2021002998A (es) Compuestos de triazolo-pirimidina y usos de los mismos.
MX2021001884A (es) Compuestos de pirazina y usos de los mismos.
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2019010202A (es) Compuestos que interactuan con glicano y metodos de uso.
MX2010014057A (es) Compuestos de piridina.
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.